Literature DB >> 17112596

Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia.

Xiaoduo Fan1, Cynthia Pristach, Emily Y Liu, Oliver Freudenreich, David C Henderson, Donald C Goff.   

Abstract

The present study examined the hypothesis that elevated serum levels of C-reactive protein (CRP) would be associated with more severe clinical symptoms in patients with schizophrenia. Twenty-six inpatients with schizophrenia or schizoaffective disorder were enrolled. Serum levels of CRP were measured, and each patient was assessed with the Positive and Negative Syndrome Scale (PANSS). Subjects with CRP levels above the normal range (CRP>0.50 mg/dl, elevated CRP group, N=5) scored significantly higher than those with CRP levels in the normal range (CRP<or=0.50 mg/dl, normal CRP group, N=21) on the PANSS total score, negative symptom subscale score and general psychopathology subscale score. There was no significant difference between the two groups on the PANSS positive symptom subscale score. An inflammatory process, as reflected by elevated serum levels of CRP, might be associated with more severe psychopathology in a subgroup of patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112596     DOI: 10.1016/j.psychres.2006.07.011

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  39 in total

1.  Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features.

Authors:  Clemente Garcia-Rizo; Emilio Fernandez-Egea; Cristina Oliveira; Azucena Justicia; Miguel Bernardo; Brian Kirkpatrick
Journal:  Psychiatry Res       Date:  2012-03-08       Impact factor: 3.222

2.  Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia.

Authors:  Jimmi Nielsen; Rasmus Røge; Sofie Gry Pristed; Anne Grethe Viuff; Henrik Ullum; Lise Wegner Thørner; Thomas Werge; Torkel Vang
Journal:  Schizophr Bull       Date:  2014-08-25       Impact factor: 9.306

Review 3.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

4.  A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.

Authors:  Brenda Vincenzi; Shannon Stock; Christina P C Borba; Sarah M Cleary; Claire E Oppenheim; Liana J Petruzzi; Xiaoduo Fan; Paul M Copeland; Oliver Freudenreich; Corinne Cather; David C Henderson
Journal:  Schizophr Res       Date:  2014-09-26       Impact factor: 4.939

5.  Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report.

Authors:  Bernhard T Baune; Harris Eyre
Journal:  J Med Case Rep       Date:  2010-01-12

6.  The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.

Authors:  X Fan; X Song; M Zhao; L F Jarskog; R Natarajan; N Shukair; O Freudenreich; D C Henderson; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2017-08-29       Impact factor: 6.392

Review 7.  The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation.

Authors:  Hervé Perron; Alois Lang
Journal:  Clin Rev Allergy Immunol       Date:  2010-08       Impact factor: 8.667

8.  Differentiating nicotine- versus schizophrenia-associated decreases of the alpha7 nicotinic acetylcholine receptor transcript, CHRFAM7A, in peripheral blood lymphocytes.

Authors:  Emily G Severance; Faith B Dickerson; Cassie R Stallings; Andrea E Origoni; Anne Sullens; Eric T Monson; Robert H Yolken
Journal:  J Neural Transm (Vienna)       Date:  2008-12-11       Impact factor: 3.575

Review 9.  Adult neurogenesis and mental illness.

Authors:  Timothy J Schoenfeld; Heather A Cameron
Journal:  Neuropsychopharmacology       Date:  2014-09-02       Impact factor: 7.853

10.  Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.

Authors:  Imran B Chaudhry; Nusrat Husain; Richard Drake; Graham Dunn; M Omair Husain; Ajmal Kazmi; Munir M Hamirani; Raza Rahman; John Stirling; William Deakin
Journal:  Ther Adv Psychopharmacol       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.